Financials data is unavailable for this security.
View more
Year on year Innovita Biological Technology Co Ltd grew revenues 7.03% from 446.62m to 478.02m while net income improved 15.44% from 150.68m to 173.95m.
| Gross margin | 80.70% |
|---|---|
| Net profit margin | 46.09% |
| Operating margin | 52.94% |
| Return on assets | 16.52% |
|---|---|
| Return on equity | 17.48% |
| Return on investment | 17.42% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Innovita Biological Technology Co Ltd fell by 212.21m. However, the company earned 259.85m from its operations for a Cash Flow Margin of 54.36%. In addition the company used 428.92m on investing activities and also paid 44.48m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 14.98 |
|---|---|
| Tangible book value per share | 14.93 |
More ▼
Balance sheet in CNYView more
| Current ratio | 16.39 |
|---|---|
| Quick ratio | 16.01 |
| Total debt/total equity | 0.001 |
|---|---|
| Total debt/total capital | 0.001 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 140.96% and 3.10%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 16.39% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 162.16 |
More ▼
